Pelthos Therapeutics Inc. Increase (Decrease) in Accrued Liabilities
Pelthos Therapeutics Inc. (PTHS) reported Increase (Decrease) in Accrued Liabilities of $6.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- Pelthos Therapeutics Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $8.31M, a 34508.33% increase year-over-year.
- Pelthos Therapeutics Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.91M.
- Pelthos Therapeutics Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-06-30 was $24.00K.
- Pelthos Therapeutics Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-03-31 was $0.00.
- Pelthos Therapeutics Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $6.16M.
- Pelthos Therapeutics Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$283.00K, a 166.73% decline from fiscal 2023.
- Pelthos Therapeutics Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $424.07K, a 91.13% increase from fiscal 2022.
- Pelthos Therapeutics Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $221.88K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8.31M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $6.40M 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | -$1.91M 10-Q/A · filed 2026-08-13 | |||||
| 2025-12-31 | $6.16M 10-K · filed 2026-03-19 | |||||
| 2025-06-30 | $24.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $24.00K 10-Q · filed 2026-08-13 | $23.64K 10-Q · filed 2025-08-13 | $23.55K derived: sum of 3 quarters · filed 2026-08-13 | $23.52K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $0.00 10-Q/A · filed 2026-08-13 | -$452.00 derived: sum of 2 quarters · filed 2026-08-13 | -$482.00 derived: sum of 3 quarters · filed 2026-08-13 | -$130.98K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2024-12-31 | -$452.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$482.00 derived: sum of 2 quarters · filed 2026-03-19 | -$130.98K derived: sum of 3 quarters · filed 2026-03-19 | -$283.00K 10-K · filed 2026-03-19 | -$282.86K 10-K · filed 2025-03-27 | |
| 2024-09-30 | -$30.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$130.53K derived: sum of 2 quarters · filed 2025-08-13 | -$282.55K 10-Q · filed 2024-11-13 | -$198.64K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-06-30 | -$130.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$282.52K 10-Q · filed 2025-08-13 | -$198.61K derived: sum of 3 quarters · filed 2025-08-13 | -$88.39K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | -$152.02K 10-Q · filed 2025-05-13 | -$68.11K derived: sum of 2 quarters · filed 2025-05-13 | $42.11K derived: sum of 3 quarters · filed 2025-05-13 | $150.05K derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $83.91K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $194.13K derived: sum of 2 quarters · filed 2025-03-27 | $302.08K derived: sum of 3 quarters · filed 2025-03-27 | $424.07K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $110.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $218.17K derived: sum of 2 quarters · filed 2024-11-13 | $340.16K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $107.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $229.94K 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $122.00K 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | $221.88K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |